RU2013110127A - Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск) - Google Patents
Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск) Download PDFInfo
- Publication number
- RU2013110127A RU2013110127A RU2013110127/10A RU2013110127A RU2013110127A RU 2013110127 A RU2013110127 A RU 2013110127A RU 2013110127/10 A RU2013110127/10 A RU 2013110127/10A RU 2013110127 A RU2013110127 A RU 2013110127A RU 2013110127 A RU2013110127 A RU 2013110127A
- Authority
- RU
- Russia
- Prior art keywords
- stage
- group
- genes
- cells
- somatic cells
- Prior art date
Links
- 210000001178 neural stem cell Anatomy 0.000 title claims abstract 14
- 210000004027 cell Anatomy 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 title 1
- 230000000392 somatic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract 11
- 210000001082 somatic cell Anatomy 0.000 claims abstract 10
- 239000003102 growth factor Substances 0.000 claims abstract 6
- 150000003384 small molecules Chemical class 0.000 claims abstract 6
- 101100163882 Mus musculus Ascl1 gene Proteins 0.000 claims abstract 5
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims abstract 5
- 230000008672 reprogramming Effects 0.000 claims abstract 5
- 101150026630 FOXG1 gene Proteins 0.000 claims abstract 4
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 claims abstract 4
- 101100445103 Mus musculus Emx2 gene Proteins 0.000 claims abstract 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract 4
- 101150020367 SOX11 gene Proteins 0.000 claims abstract 4
- 239000003112 inhibitor Substances 0.000 claims abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000011435 rock Substances 0.000 claims abstract 4
- 239000000126 substance Substances 0.000 claims abstract 4
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims abstract 3
- 101150081664 PAX6 gene Proteins 0.000 claims abstract 3
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims abstract 2
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 claims abstract 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract 2
- 102000004877 Insulin Human genes 0.000 claims abstract 2
- 108090001061 Insulin Proteins 0.000 claims abstract 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims abstract 2
- 102000004338 Transferrin Human genes 0.000 claims abstract 2
- 108090000901 Transferrin Proteins 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims abstract 2
- 210000001789 adipocyte Anatomy 0.000 claims abstract 2
- 210000002950 fibroblast Anatomy 0.000 claims abstract 2
- 210000005260 human cell Anatomy 0.000 claims abstract 2
- 230000006698 induction Effects 0.000 claims abstract 2
- 229940125396 insulin Drugs 0.000 claims abstract 2
- 210000002510 keratinocyte Anatomy 0.000 claims abstract 2
- 239000002609 medium Substances 0.000 claims abstract 2
- RHEUKGKHEYZGDL-FGZHOGPDSA-N n-[(3r,4r)-4-[[4-(2-fluoro-6-hydroxy-3-methoxybenzoyl)benzoyl]amino]azepan-3-yl]-4-hydroxy-3,5-dimethylbenzamide Chemical compound COC1=CC=C(O)C(C(=O)C=2C=CC(=CC=2)C(=O)N[C@H]2[C@@H](CNCCC2)NC(=O)C=2C=C(C)C(O)=C(C)C=2)=C1F RHEUKGKHEYZGDL-FGZHOGPDSA-N 0.000 claims abstract 2
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960003387 progesterone Drugs 0.000 claims abstract 2
- 239000000186 progesterone Substances 0.000 claims abstract 2
- 230000035755 proliferation Effects 0.000 claims abstract 2
- 239000012679 serum free medium Substances 0.000 claims abstract 2
- 239000012581 transferrin Substances 0.000 claims abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010874 in vitro model Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ получения нейральных стволовых клеток (НСК), включающий:а) получение соматических клеток,б) репрограммирование указанных соматических клеток в НСК с помощью введения по меньшей мере двух генов из группы Bmi1, Sox2, Mash1, Sox11, Emx2, Foxg1 и Рах6; ив) индукцию репрограммирования с помощью ростовых факторов и малой молекулы.2. Способ по п.1, дополнительно включающийг) инкубацию продуктов стадий б) и в) в условиях, подходящих для пролиферации НСК.3. Способ по п.1, где соматические клетки стадии а) являются клетками человека.4. Способ по п.1, где соматические клетки стадии а) выбраны из группы фибробластов, кератиноцитов или адипоцитов.5. Способ по п.1, где факторы роста и малая молекула стадии в) являются добавками в среду определенного химического состава.6. Способ по п.5, где среда определенного химического состава является бессывороточной средой с добавлением инсулина, трансферрина и прогестерона.7. Способ по п.1, где по меньшей мере два гена стадии б) включают Bmi1 и Sox2.8. Способ по п.7, где по меньшей мере два гена стадии б) дополнительно включают по меньшей мере один ген, выбранный из группы Mash1, Sox11, Emx2, Foxg1 и Рах6.9. Способ по п.7 или п.8, где по меньшей мере два гена стадии б) включают Bmi, Sox2 и Mash1.10. Способ по п.1, где фактор роста стадии в) выбран из группы FGF2, EGF и BDNF.11. Способ по п.1, где малая молекула стадии в) включает ингибитор ROCK.12. Способ по п.11, где ингибитор ROCK выбран из группы 1-(5-изокинолинсульфонил)гомопиперазина, N-бензил-2-(пиримидин-4-иламино)тиазол-4-карбоксамида, (+)-(R)-транс-4-(1-аминоэтил)-N-(4-пиридил)циклогексанкарбоксамида дигидрохлорида и N-{(3R,4R)-4-[4-(2-фтор-6-гидрокси-3-метокси-бензоил)-бензоиламино]-азепан-3-ил}-4-гидрокси-3,5-диметилбензамида.
Claims (19)
1. Способ получения нейральных стволовых клеток (НСК), включающий:
а) получение соматических клеток,
б) репрограммирование указанных соматических клеток в НСК с помощью введения по меньшей мере двух генов из группы Bmi1, Sox2, Mash1, Sox11, Emx2, Foxg1 и Рах6; и
в) индукцию репрограммирования с помощью ростовых факторов и малой молекулы.
2. Способ по п.1, дополнительно включающий
г) инкубацию продуктов стадий б) и в) в условиях, подходящих для пролиферации НСК.
3. Способ по п.1, где соматические клетки стадии а) являются клетками человека.
4. Способ по п.1, где соматические клетки стадии а) выбраны из группы фибробластов, кератиноцитов или адипоцитов.
5. Способ по п.1, где факторы роста и малая молекула стадии в) являются добавками в среду определенного химического состава.
6. Способ по п.5, где среда определенного химического состава является бессывороточной средой с добавлением инсулина, трансферрина и прогестерона.
7. Способ по п.1, где по меньшей мере два гена стадии б) включают Bmi1 и Sox2.
8. Способ по п.7, где по меньшей мере два гена стадии б) дополнительно включают по меньшей мере один ген, выбранный из группы Mash1, Sox11, Emx2, Foxg1 и Рах6.
9. Способ по п.7 или п.8, где по меньшей мере два гена стадии б) включают Bmi, Sox2 и Mash1.
10. Способ по п.1, где фактор роста стадии в) выбран из группы FGF2, EGF и BDNF.
11. Способ по п.1, где малая молекула стадии в) включает ингибитор ROCK.
12. Способ по п.11, где ингибитор ROCK выбран из группы 1-(5-изокинолинсульфонил)гомопиперазина, N-бензил-2-(пиримидин-4-иламино)тиазол-4-карбоксамида, (+)-(R)-транс-4-(1-аминоэтил)-N-(4-пиридил)циклогексанкарбоксамида дигидрохлорида и N-{(3R,4R)-4-[4-(2-фтор-6-гидрокси-3-метокси-бензоил)-бензоиламино]-азепан-3-ил}-4-гидрокси-3,5-диметилбензамида.
13. Способ по п.1, где соматические клетки предварительно обработаны ингибитором деацетилазы гистонов (HDAC).
14. Способ по п.1, где репрограммирование указанных соматических клеток достигается доставкой комбинации по меньшей мере двух генов с помощью лентивируса.
15. Нейральные стволовые клетки, полученные способом по любому из пп.1-14.
16. Применение нейральных стволовых клеток по п.15 в качестве in vitro модели заболеваний ЦНС.
17. Терапевтическая композиция, включающая нейральные стволовые клетки по п.15.
18. Терапевтическая композиция по п.17, где нейральные стволовые клетки дифференцируются в нейроны или клетки глии.
19. Биобанк НСК, полученных с помощью способа по любому из пп.1-14.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10173455 | 2010-08-19 | ||
| EP10173455.6 | 2010-08-19 | ||
| PCT/EP2011/064051 WO2012022725A2 (en) | 2010-08-19 | 2011-08-16 | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013110127A true RU2013110127A (ru) | 2014-09-27 |
| RU2562111C2 RU2562111C2 (ru) | 2015-09-10 |
Family
ID=43734036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110127/10A RU2562111C2 (ru) | 2010-08-19 | 2011-08-16 | Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск) |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9297025B2 (ru) |
| EP (1) | EP2606126B1 (ru) |
| JP (1) | JP5905006B2 (ru) |
| KR (2) | KR101788903B1 (ru) |
| CN (1) | CN103068974B (ru) |
| BR (1) | BR112013003031A2 (ru) |
| CA (1) | CA2807226A1 (ru) |
| ES (1) | ES2580837T3 (ru) |
| HK (1) | HK1184492A1 (ru) |
| MX (1) | MX348419B (ru) |
| RU (1) | RU2562111C2 (ru) |
| WO (1) | WO2012022725A2 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013003031A2 (pt) | 2010-08-19 | 2016-06-14 | Hoffmann La Roche | método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs |
| CN102604894B (zh) | 2012-02-29 | 2014-07-30 | 中国科学院广州生物医药与健康研究院 | 用于制备神经干细胞的培养基及其用途 |
| PL223189B1 (pl) * | 2012-11-15 | 2016-10-31 | Celther Polska Spółka Z Ograniczoną Odpowiedzialnością | Komórka iNS oraz sposób reprogramowania komórek somatycznych za pomocą czynnika Sox2 oraz Sox2 i c-Myc do komórki iNS |
| EA035349B1 (ru) * | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
| KR20140121317A (ko) | 2013-04-06 | 2014-10-15 | 서울대학교산학협력단 | 비신경 세포로부터 유도 신경 줄기 세포의 생산 방법 및 이에 의하여 생산되는 유도 신경 줄기 세포 |
| EP3024928B1 (en) | 2013-07-23 | 2018-11-21 | F. Hoffmann-La Roche AG | Small molecule based conversion of somatic cells into neural crest cells |
| CN104342401B (zh) * | 2013-07-25 | 2017-04-05 | 中国科学院广州生物医药与健康研究院 | 利用确定的细胞因子组合促进成纤维细胞转分化为脂肪细胞 |
| DK3060237T3 (da) * | 2013-10-25 | 2021-10-25 | Univ Wayne State | Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer |
| EP3088415B1 (en) | 2013-12-25 | 2019-11-06 | Toagosei Co., Ltd. | Method for inducing differentiation of pluripotent stem cells into endodermal cells |
| CN104894060B (zh) * | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | 诱导体细胞转分化为神经干细胞的方法及其应用 |
| CN104195108B (zh) * | 2014-07-29 | 2018-02-06 | 深圳市三启生物技术有限公司 | 蛋白激酶抑制剂在从非神经细胞制备神经细胞中的用途 |
| EP3265556A4 (en) * | 2015-03-04 | 2018-08-22 | The University of North Carolina at Chapel Hill | Methods for making neural stem cells and uses thereof |
| US11027047B2 (en) | 2015-03-31 | 2021-06-08 | The University Of North Carolina At Chapel Hill | Delivery vehicles for stem cells and uses thereof |
| JP6691756B2 (ja) | 2015-09-29 | 2020-05-13 | 東亞合成株式会社 | 合成ペプチドを用いた神経幹細胞の生産方法 |
| ES2852998T4 (es) * | 2015-11-12 | 2024-04-25 | Hoffmann La Roche | Oligonucleótidos para inducir la expresión de UBE3A paterno |
| CA3019089A1 (en) * | 2016-03-31 | 2017-10-05 | Ajinomoto Co., Inc. | Medium for neural stem cells enhancing neural differentiation ability |
| EP3447126A4 (en) * | 2016-04-20 | 2019-11-13 | Kyoto Prefectural Public University Corporation | PROCESS FOR PRODUCING SHEET OF CULTIVATED EPITHELIAL CELLS |
| WO2019004533A1 (ko) * | 2017-06-30 | 2019-01-03 | 주식회사 스템랩 | 소변세포로부터 케라티노사이트 줄기세포로의 직접 역분화 방법 및 역분화된 케라티노사이트 줄기세포를 이용한 피부재생 촉진용 조성물의 제조방법 |
| EP3807402A4 (en) * | 2018-06-14 | 2022-04-27 | Academia Sinica | METHOD FOR GENERATE INDUCED OLIGODENDROCYTE LINEAGE CELLS AND TREATMENT USING SUCH CELLS |
| WO2020038851A1 (en) | 2018-08-21 | 2020-02-27 | F. Hoffmann-La Roche Ag | Methods for assessing transendothelial barrier integrity |
| AU2020453143A1 (en) * | 2020-06-09 | 2023-02-09 | Unist(Ulsan National Institute Of Science And Technology) | Composition for inducing direct cross differentiation of somatic cell into motor neuron, and method for using same |
| CA3197178A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Neurod1 combination vector |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968829A (en) * | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| PL374557A1 (en) * | 2001-11-09 | 2005-10-31 | Artecel Sciences, Inc. | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
| WO2004007700A1 (ja) * | 2002-06-24 | 2004-01-22 | Tanabe Seiyaku Co., Ltd. | 神経系細胞の製造方法 |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| WO2005095450A2 (en) * | 2004-03-30 | 2005-10-13 | Nsgene A/S | Therapeutic use of a growth factor, nsg33 |
| GB0410011D0 (en) * | 2004-05-05 | 2004-06-09 | Novartis Forschungsstiftung | Neural cell differentiation method |
| US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US20100021437A1 (en) * | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
| WO2010018996A2 (ko) * | 2008-08-12 | 2010-02-18 | 연세대학교 산학협력단 | 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물 |
| GB0902034D0 (en) * | 2009-02-06 | 2009-03-11 | Reneuron Ltd | Method |
| BR112013003031A2 (pt) | 2010-08-19 | 2016-06-14 | Hoffmann La Roche | método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs |
-
2011
- 2011-08-16 BR BR112013003031A patent/BR112013003031A2/pt active Search and Examination
- 2011-08-16 JP JP2013524439A patent/JP5905006B2/ja active Active
- 2011-08-16 MX MX2013001587A patent/MX348419B/es active IP Right Grant
- 2011-08-16 CN CN201180040130.2A patent/CN103068974B/zh not_active Expired - Fee Related
- 2011-08-16 WO PCT/EP2011/064051 patent/WO2012022725A2/en active Application Filing
- 2011-08-16 KR KR1020137003961A patent/KR101788903B1/ko active IP Right Grant
- 2011-08-16 RU RU2013110127/10A patent/RU2562111C2/ru not_active IP Right Cessation
- 2011-08-16 CA CA2807226A patent/CA2807226A1/en not_active Abandoned
- 2011-08-16 ES ES11743246.8T patent/ES2580837T3/es active Active
- 2011-08-16 KR KR1020167007305A patent/KR20160033798A/ko not_active Application Discontinuation
- 2011-08-16 EP EP11743246.8A patent/EP2606126B1/en not_active Not-in-force
-
2013
- 2013-02-18 US US13/769,762 patent/US9297025B2/en not_active Expired - Fee Related
- 2013-10-22 HK HK13111852.9A patent/HK1184492A1/zh not_active IP Right Cessation
-
2016
- 2016-02-18 US US15/046,885 patent/US20160369234A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5905006B2 (ja) | 2016-04-20 |
| ES2580837T3 (es) | 2016-08-29 |
| WO2012022725A3 (en) | 2012-04-12 |
| MX348419B (es) | 2017-06-12 |
| MX2013001587A (es) | 2013-03-21 |
| EP2606126A2 (en) | 2013-06-26 |
| CA2807226A1 (en) | 2012-02-23 |
| JP2013535973A (ja) | 2013-09-19 |
| CN103068974A (zh) | 2013-04-24 |
| BR112013003031A2 (pt) | 2016-06-14 |
| US20140051171A1 (en) | 2014-02-20 |
| US9297025B2 (en) | 2016-03-29 |
| RU2562111C2 (ru) | 2015-09-10 |
| WO2012022725A2 (en) | 2012-02-23 |
| HK1184492A1 (zh) | 2014-01-24 |
| EP2606126B1 (en) | 2016-05-18 |
| KR20160033798A (ko) | 2016-03-28 |
| CN103068974B (zh) | 2016-05-11 |
| US20160369234A1 (en) | 2016-12-22 |
| KR101788903B1 (ko) | 2017-10-23 |
| KR20130030303A (ko) | 2013-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013110127A (ru) | Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск) | |
| Peschansky et al. | Non-coding RNAs as direct and indirect modulators of epigenetic regulation | |
| NZ530782A (en) | Aminoisoxazole derivatives active as kinase inhibitors | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2014005331A (es) | Compuestos de heteroaril piridona y aza-piridona. | |
| MX2014005289A (es) | Compuestos de piperazina alquilados. | |
| UA103092C2 (ru) | Производные нафталинкарбоксамида как ингибиторы протеинкиназы и гистондеацетилазы, способ их получения и применения | |
| IL288181B1 (en) | Cancer treatment methods | |
| EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
| MY160349A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| MY149143A (en) | Thiazole compounds as protien kinase b (pkb) inhibitors | |
| BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
| NZ590372A (en) | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) | |
| DK1751093T3 (da) | Substituerede cyklohexyleddikesyre-derivater | |
| MY155230A (en) | Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine | |
| WO2011097181A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders | |
| NO20083639L (no) | Aurorakinasemodulatorer og fremgangsmate for anvendelse | |
| WO2008011080A3 (en) | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine | |
| MY189592A (en) | Method for producing cerebellar progenitor tissue | |
| CN107454913A (zh) | 使用小分子化合物使人成纤维细胞直接转化为神经干细胞的方法 | |
| NI200700311A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3 | |
| MX2010004876A (es) | Derivados de diamido tiazol como inhibidores de la proteina cinasa. | |
| CN103740757A (zh) | 一种利用重编程制备猪神经干细胞的方法 | |
| RU2016105998A (ru) | Конверсия на основе малых молекул соматических клеток в клетки нейрального гребня | |
| EP3269803A3 (en) | Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 25-2015 FOR TAG: (54) |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180817 |